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Impact of prior statin therapy on 
evaluation of the inflammatory 
process and cortisol concentration 
in patients with the first ST-segment 
elevation myocardial infarction 
undergoing coronary angioplasty  
with bare metal stent implantation
ABSTRACT
Introduction. The aim of the current study was to verify the impact of statin therapy on evaluation of the 
inflammatory process and cortisol concentration in patients with the first episode of ST-segment elevation 
myocardial infarction undergoing coronary angioplasty with bare metal stent implantation. 
Material and methods. The study was designed as a prospective, single-center cohort study, with a total 
number of 200 patients enrolled between 2005 and 2008. 
Results. Seventeen patients with ongoing statin therapy and 167 patients without those agents underwent 
pPCI with BMS implantation. The cortisol concentration on admission was significantly lower in statin 
therapy subgroup — median 14.9 µg/dL (9.5–23.3 IQR) vs. 28,1 µg/dL (17.2–39.9 IQR) for patients without 
lipid lowering drug, p = 0.01. The level of cortisol after 23h was also significantly lower in statin receiving 
subgroup: 10.4 µg/dL (8.3–19 IQR) vs. 17.3 µg/dL (10.1–25.9 IQR) adequately, p = 0.021. Those two 
groups did not differ significantly in relation to CRP, IL-6, IL-10 concentrations and to anti-inflammatory 
cytokine ratio [IL-6/IL-10] on admission, after 24h and at discharge. Significant differences were observed 
in the concentrations of cTnI and activities of CK and CK-MB. 
Conclusions. Ongoing statin therapy before an episode of myocardial infarction has an influence on cortisol 
concentration and cardiac markers. No significant effect on serum levels of cytokines has been observed.
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Introduction
Over the past few years, an increased interest in the 
course of the inflammatory process associated with the 
onset and implemented treatment of acute coronary 
syndromes has been observed. Many factors that can 
have influence on the course of the acute coronary 
syndrome (ACS), effectiveness of treatment and the 
prognosis have been described. There are only a few 
studies referring to the analysis of the inflammatory 
process in a large homogeneous group of patients with 
the first episode of myocardial infarction undergoing 
primary coronary angioplasty with stent implementation. 
The relationship between the humoral pro- and anti-in-
flammatory response and factors associated with the 
performance of primary angioplasty procedures are still 
not fully understood. Understanding the mechanisms 
related to the course of acute ischemia and reperfusion 
may help to identify groups of patients at the highest 
risk and improve the effectiveness of treatment. 
Low serum cortisol concentrations have been 
associated with adverse prognosis in critical illness of 
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diverse etiology. There are only few previous studies 
on the association between cortisol concentration and 
prognosis after acute myocardial infarction and results 
are conflicting [1–6].
The aim of the current study was to verify the impact 
of statin therapy on the evaluation of inflammatory pro-
cess, cortisol level and cardiac markers in patients with 
the first episode of ST-segment elevation myocardial 
infarction undergoing coronary angioplasty with bare 
metal stent implantation.
Methods
Study design and participants
The study was designed as a prospective, single-cen-
ter cohort study with 200 patients enrolled. All of the 
patients were hospitalized in the Cardiology and Internal 
Diseases Department of the University Hospital No. 1 
in Bydgoszcz due to the first episode of ST-elevation 
myocardial infarction. Patients were recruited between 
1st November 2005 and 1st November 2008. All of the re-
cruited patients underwent coronary angiography. Based 
on angiography findings: 6 patients underwent primary 
coronary angioplasty without stenting, 1 patient was di-
agnosed with Takotsubo cardiomyopathy, 9-patients 
underwent primary PCI with drug eluting stent implantation 
(DES), and bare metal stents (BMS) were implanted in the 
remaining 184 patients. Only 17 patients out of the whole 
study population were previously treated with statins.
Myocardial infarction was diagnosed based on the 
occurrence of clinical symptoms (typical chest pain) 
and ECG changes: ST-segment elevation > 2 mm in the 
precordial leads and > 1 mm in the limb leads. Standard 
physical examination, laboratory tests, electrocardiog-
raphy and echocardiography were performed during 
hospitalization. In the analyzed population, selected 
markers of inflammation were determined: on admission 
to the hospital, after 24 hours of hospitalization and at 
discharge. Three months after hospitalization every 
patient was closely inspected.
Exclusion criteria were: age > 80 years, heart failure 
in class III or IV according to NYHA, SBP > 200 mm Hg 
and/or DBP > 100 mm Hg, cardiomyopathies, hemo-
dynamically significant valvular heart disease or history 
of valvular cardiac surgery, previous PCI or CABG, 
electrical stimulation of the heart, advanced chronic 
obstructive pulmonary disease, cancer, severe disease 
of other organs, prior surgery within 2 months, thrombo-
cythopenia with platelet count < 100,000/mm3, the cre-
atinine clearance > 2 mg/dL or dialysis, arteriosclerosis 
obliterans of the lower limbs, clinically overt infection, 
alcohol abuse, statement when the collaboration with 
the patient was impossible. The study was approved by 
the institutional review board and independent ethics 
committee. All patients enrolled in the study signed 
informed consent forms.
Procedures
Coronary angiography and percutaneous translu-
minal coronary angioplasty (PTCA) were performed 
using standard technique with the access from the fem-
oral artery. Non-ionic contrast agents were used. The 
presence of residual stenosis of 20% of the reference 
segment diameter or lack of stenosis were treated as 
optimal treatment outcomes. Patients received 0.3 mg of 
nitroglycerin intracoronary if the blood pressure allowed. 
All angiograms were evaluated by two independent 
invasive cardiologists — they had no access to clinical, 
electrocardiographic and echocardiographic data. The 
flow in the vessel was assessed by TIMI (Thrombolysis in 
Myocardial Infarction) and TIMI frame count (TFC) scores.
After the procedure, all patients received: clopido-
grel (75 mg/day), acetylsalicylic acid (75 mg/day) and 
simvastatin (40 mg/day). In addition, in the majority of 
patients throughout the study period, ACEI and B-block-
er in doses adapted to the value of blood pressure and 
heart rate (Tab. 1) were used. 
Laboratory tests
Standard biochemical tests in patients with acute MI 
(BNP, complete blood cell count, CRP, electrolytes, cre-
atinine clearance, lipids, fibrinogen, APTT, INR, HBs Ag, 
anti-HCV, blood group, BUN, glycaemia, HbA1c, lipid 
levels) were performed: on admission to the hospital, 
after 24 hours and at discharge. Cardiac markers (CK, 
CK-MB, TnI) on admission and after 6, 12 and 12 h. 
Determination of cytokines (Il-6, Il-10) was scheduled as 
follows: on admission, after 24 hours of hospitalization, 
at discharge from hospital; cortisol concentration was 
assessed on admission, after 8 and 23 hours. In order 
to standardize the tests, in the first ten patients, blood 
samples were taken from the antecubital vein and fem-
oral artery before angiography. The results showed no 
significant differences between the concentrations of 
cytokines assayed from both of the vessels, so all the 
blood samples, during the study period, were taken from 
antecubital vein. From every patient, 10 mL of blood 
was collected into citrate tubes, and then centrifuged 
for 20 minutes at 3000 rpm. The centrifuged plasma 
was frozen at < –70°C and stored until the analysis was 
performed. The tests were performed using CBA Flex 
Sets tests (Becton Dickinson, Franklin Lakes, USA). 
Electrocardiography and echocardiography
The standard 12-lead, resting electrocardiogram 
was performed at admission, before coronary angio-
graphy and before discharge. At discharge, transthoracic 
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echocardiography, according to the protocol recom-
mended by the American Society of Echocardiography, 
was also performed. 
Statistical analysis
The statistical analysis was carried out using the 
Statistica 10 package. Due to fact that data distribution 
was different from normal, based on the Shapiro-Wilk 
W-test and the Kolmogorov-Smirnov, the results are pre-
sented as the median value and IQ range for quantitative 
parameters and as percentage of the population for 
qualitative parameters. Significance of the differences 
was evaluated using non-parametric Mann-Whitney 
U-test or Kruskal-Wallis ANOVA. The Wilcoxon signed 
rank test was used to evaluate dependent samples 
and Spearman’s rank test for correlation. The c2 test 
(and with the Yates correction if needed) was used 
for qualitative variables. A difference was considered 
significant at p < 0.05.





Median (IQR) n (%)
Statin (–)
(n = 167)
Median (IQR) n (%)
p
On admission:
Age (years) 63 (51–68) 55 (50–62) ns
BMI [kg/m2] 28.26 (26.84–29.11) 26.31 (24.11–29.06) ns
Abdominal circumference [cm] 105.0 (96.5–110.0) 98.5 (90.0–106.0) p = 0.033
Glycaemia [mmol/L] 7.11 (6.22–9.06) 7.61 (6.72–9.22) ns
HbA1c (%) 6.1 (5.5–6.9) 6.0 (5.6–6.6) ns
Creatinine level [µmol/L] 79.56 (70.72–88.4) 83.98 (76.91–97.24) ns
LVEF (%) 46.0 ( 43.0–49.9) 45.0 (40.0–50.0) ns
BNP [pg/mL] 109.2 (47.6–146.7) 47.1 (25.3–85.8) ns
BNP at discharge [pg/mL] 124.1 (37.4–169.1) 114.0 (69.9–215.9) ns
Male gender 13 (76.47%) 129 (77.25%) ns
Hypertension 9 (52.94%) 64 (38.32%) ns
Diabetes mellitus 4 (23.53%) 22 (13.17%) ns
Current smokers or history of smoking 9 (52.94%) 114 (68.26%) ns
Family history of CVD 2 (11.76%) 36 (21.56%) ns
Location of AMI anterior 6 (35.29%) 68 (40.72%) ns
Angina prior AMI (CCS I–IV) 12 (70.59%) 13 (44.83%) ns
TMPG 3 12 (70.59%) 77 (46.11%) ns
Lipidogram [mmol/L]:
Total cholesterol 4.47 (4.01–5.84) 5.82 (5.17–6.57) p = 0.007
LDL 2.79 (2.28–3.75) 3.8 (3.31–4.60) p < 0.001
HDL 1.37 (1.19–1.45) 1.31 (1.16–1.53) ns
TG 0.75 (0.49–1.56) 1.02 (069–1.64) ns
At discharge:
LAD — target vessel 6 (35.29%) 71 (42.51%) ns
Stents 1 vs. 2/3 2 (11.76%) 30 (11.98%) ns
Multivessel CAD 10 (58.82%) 100 (59.88%) ns
TIMI 0 before PCI 4 (23.53%) 93 (55.69%) p = 0.01
TIMI 3 after PCI 17 (100%) 155 (92.81%) ns
IIb/IIIa receptors blocker 1 (5.882%) 44 (26.35%) p = 0.033
IQR — interquartile range; BMI — body mass index; LVEF — ventricular ejection fraction; BNP — brain natriuretic peptide; CVD — cardiovascular 
diseases; AMI — acute myocardial infarction; TMPG —TIMI myocardial perfusion grade; TIMI — thrombolysis in myocardial infarction; LDL — 
low-density lipoprotein; HDL — high-density lipoprotein; TG — triglycerides; LAD — left artery descending
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Between March 25, 2005 and May 7, 2007, a total num-
ber of 200 patients, from our center, who had ST-segment 
elevation myocardial infarction and undergone primary 
PCI with bare metal stent, were included into the study.
Before the hospitalization, only 17 patients were 
treated with statins (9.24%); 13 patients had received 
simvastatin and 4 atorvastatin. 
Those two subgroups did not differ in terms of the 
location of the myocardial infarction, the number of infarct 
related vessels and flow rates in the target vessel (Tab. 1). 
However, the percentage of patients with TIMI 0 before stent 
implantation was higher in the group not receiving statins 
(55.69% vs. 23.53%, p = 0.01). Population treated with 
statins was characterized by a larger abdominal circumfer-
ence (median 105.0 vs. 98.5 cm, p = 0.033), lower levels of 
total cholesterol (median 4.47 vs. 5.82 mmol/L, p = 0.007) 
and LDL cholesterol (median 2.79 vs. 3.80 mmol/L, 
p < 0.001). Significant differences in drug patterns prior 
AMI were noted at admission (Tab. 2).
Interesting differences in cardiac markers pro-
files were identified in both subgroups. In spite of 
comparable activity of CK (204 vs. 169 U/L), CK-MB 
(31 vs. 26 U/L) and cTnI (0.35 vs. 0.26 µg/L) on admis-
sion, the higher levels of CK-MB and TnI were observed 
after 6 h, 12 h and 24 h in population not previously 
treated by statin (Tab. 3, Fig. 1).
It was also noted that in statin group maximum 
cTnI levels (median 15 vs. 30.47.04 µg/L, p < 0.022) 
and maximum CK-MB (median 54.00 vs. 103.00 U/L, 
p = 0.010) were significantly lower.
Table 2. Drugs prior to acute myocardial infraction (AMI)
Drugs Statin (+)
(n = 17)
Median (IQR) n (%)
Statin (–)
(n = 167)
Median (IQR) n (%)
p
Aspirin 7 (41.18%) 7 (4.19%) p < 0.001
ACE inhibitors/AT1 blockers 6 (35.294%) 20 (11.98%) p = 0.020
B-blockers 5 (29.41%) 11 (6.59%) p = 0.008
Calcium channel blocker 5 (29.41%) 10 (5.995%) p = 0.005
Diuretics 1 (5.88%) 0 ns
ACE — angiotensin-converting enzyme
Table 3. Comparison of the levels of cardiac markers concentrations at subsequent time endpoints in two subgroups: 





Median (IQR) n (%)
Statin (–)
(n = 167)
Median (IQR) n (%)
p
On admission:
CPK 204 (134–345) 169 (106–315) ns
CK-MB 31 (18–53) 25 (18–42) ns
TnI 0.35 (0.09–1.18) 0.26 (0.06–1.01) ns
6 h after PCI:
CPK 642 (436–2041) 1849 (824–3596) ns
CK-MB 82 (62–216) 257 (125–437) p = 0.003
TnI 15.42 (6.72–43.35) 48.17 (12.85–50.0) p = 0.027
12 h after PCI:
CPK 642 (480–1707) 1645 (782–2770) p = 0.009
CK-MB 81 (60–151) 206 (119–335) p = 0.001
24 h after PCI:
CPK 351 (323–1104) 1000 (506–1631) p = 0.01
CK-MB 45 (40–73) 99 (59–154) p = 0.001
CPK — creatine phosphokinase; CK-MB — MB isoenzyme of creatine kinase; TnI — cardiac-specific troponin I
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In the whole analyzed population, maximum cTnI 
concentration and CK-MB maximum activity significantly 
correlated with CRP after 24 h (r = 0.454, p < 0.001; 
r = 0.472, p < 0.001 respectively) and CRP level at 
discharge (r = 0.325, p < 0.001; r = 0.363, p < 0.001 re-
spectively) but no differences between both groups 
were found. 
Comparative analysis of concentrations and ratios 
of cytokines 
CRP level. The level of C-reactive protein on ad-
mission to the hospital (Tab. 4) was: 1.57 mg/L (IQR 
4.62) vs. 1.84 mg/L (IQR 9.38) for previously treated 
and not treated with statins respectively. CRP level after 
24 hours: median 9 mg/L (IQR 48.19) vs. 10.59 mg/L 
(IQR 107.1) adequately (p = 0.255). The two groups 
differed significantly in CRP concentration only at 
discharge: median 7.24 mg/L (IQR 30.44) for patients 
treated vs. 11.13 mg/L (IQR 72.66) for those not treated 
with HMG-Co A inhibitors, p = 0.018.
Concentration changes patterns in both groups 
were similar. Significant increase of CRP concentration 
between on admission vs. after 24 h was observed 
(p < 0.05) and non-significant change occurred from 
24h up to at discharge (Fig. 2). 
Interleukin 6. The concentrations of pro-inflammato-
ry IL-6 on admission to the hospital were similar between 
the subgroups: median 14.359 pg/mL (IQR 85.277) 
for patients treated vs. 12.462 pg/mL (IQR 1498.684) 
for those not treated with statin, p = 0.093. IL-6 levels 
after 24 hours were as follows: median 25.958 ng/mL 
(IQR 54.085) vs. 25.69 ng/mL (IQR 582.633) for pre-
viously treated and not treated with HMG-Co A inhib-
itors (p = 0.948). The level of cytokine at discharge 
was: 12.706 ng/mL (IQR 65.055) vs. 16,203 ng/mL 
(IQR663.365) respectively. Only in one patient not 
treated previously with statin, significant increase of 
IL-6 concentration between on admission vs. after 
24 h (p < 0.05) and decrease from 24h till discharge 
(p < 0.05) was identified (Fig. 3).
Interleukin 10. The concentration of anti-inflammatory 
IL-10 on admission was significantly lower among patients 
form the statin therapy subgroup — median 12.93 pg/mL 
(IQR 97.305) vs. 15.495 pg/mL (IQR 1115.259) for pa-
tients without lipid lowering drug, p = 0.035. IL-10 level 
after 24 hours was as follows: median 14.635 pg/mL 
Table 4. Comparison of the levels of acute phase proteins and cortisol at subsequent time endpoints in two 










CRP on admission 1.57 (0.87–2.37) 1.84 (1.02–3.27) ns
CRP 24 h 9(5.14–10.8) 10.59 (5.85–21.2) ns
CRP at discharge 7.24 (5.48–11.26) 11.13 (5.27–17.75) p = 0.018
IL-6 on admission 14.359 (6.285–26.335) 12.462 (7.944–26.763) ns
IL-6 24 h 25.958 (12.396–0.625) 25.69 (13.841–4.945)  ns
IL-6 at discharge 12.706 (2.19–9.128) 16.203 (8.425–29.157) ns
IL-10 on admission 12.93 (10.809–26.537) 15.495 (9.396–30.649) p = 0.01
IL-10 24 h 14.635 (10.955–21.364) 15.693 (8.951–29.293) ns
IL-10 at discharge 8.766 (2.682–27.804) 14.79 (5.452–23.628) ns
Cortisol on admission 14.9 (9.5–23.3) 28.1 (17.2–39.9) p = 0.010
Cortisol 8 h 17.4 (15.5–20.8) 20 (15.6–24) p = 0.220
Cortisol 23 h 10.4 (8.3–19) 17.3 (10.1–25.9) p = 0.021
CRP — C-reactive protein; IL — interleukin
Figure 1. Differences in concentration of MB isoenzyme 
of CK (CK-MB) in two subgroups of patients: treated and 
not treated with statin before hospitalization during the first 
day of hospitalization
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(IQR 68.848) vs. 15.693 pg/mL (IQR 1428.645) for previ-
ously treated and not treated with statin (p = 0.399). The 
level of cytokine at discharge did not differ significantly 
but was greater in the statin subgroup: 8.766 pg/mL (IQR 
57.383) vs. 14.792 (IQR 563.043). 
Proportion of cytokines. All the comparisons of the 
proportion of the levels of cytokines in subsequent time 
endpoints did not reach statistical significance. The ratio 
between IL-6 and IL-10 on admission was: 0.897 me-
dian (IQR 3.698) vs. 0.807 (IQR 26.543) for patients 
with and without statin therapy before admission to the 
hospital (p = 0.341); after 24 hours — 1.663 (IQR 2.199) 
vs. 1.392 (IQR 15.804) (p = 0.414); at discharge it was 
— 1.145 (IQR 4.738) vs. 1.045 (IQR 24.968) (p = 0.497). 
Cortisol concentration. The concentration of serum 
cortisol on admission was significantly lower among 
patients in the statin therapy subgroup (Tab. 4) — me-
dian 14.9 µg/dL (IQR 13.8) vs. 28.1 µg/dL (IQR 22.7) 
for patients without statin therapy, p = 0.01. Cortisol 
level (Fig. 4) after 8 hours was: in the patients previ-
ously treated with statins — median 17,4 µg/dL (IQR 
5.3) vs. 20 µg/dL (IQR 8.4) in those not treated with 
statins (p = 0.22). The level of steroid at discharge 
was significantly lower in patients who received statin 
previously: 10.4 µg/dL (IQR 10.7) vs. 17.3 µg/dL (IQR 
15.8) for patients without statin therapy before hospi-
talization, p = 0.021. 
Comparative analysis of pre-specified subgroups: 
patients with hyperlipidemia treated with statin, 
patients with hyperlipidemia without lipid lowering 
drugs, patients without hyperlipidemia
Close inspection in the pre-specified subgroups 
has shown a lack of disparity between concentration 
of CRP, concentration of IL-6 and IL-10. It also revealed 
significant differences in cortisol level on admission 
and non-significant but visible at 8 and 23 hours after 
admission. Cortisol concentration on admission and 
after 23 hours was meaningfully lower in patients with 
prior lipid lowering therapy (on admission — median 
14.9 µg/dL (IQR 9.5–23.3) for patients on statin ther-
apy before episode of MI vs. 29.4 µg/dL (IQR 22.4) 
for patients with hyperlipidemia and without statins 
vs. 27.95 µg/dL (IQR 22.2) for patients without lipid 
disturbances, p = 0,035; after 8 h — 17.4 µg/dL (IQR 
5.3) vs. 22.4 µg/dL (IQR 6.3) vs. 19.75 µg/dL (IQR 9.7) 
respectively, p = 0.055; after 23 h — 10.4 µg/dL (IQR 
Figure 2. Dynamics of changes in the concentrations of cytokines at the subsequent measurement endpoints in two 
subgroups of patients: treated and not treated with statin before hospitalization (on admission, 24 h after primary PCI, 
at discharge)
Figure 3. Dynamics of changes in the concentrations of 
IL-6 at the subsequent measurement endpoints in two 
subgroups of patients: treated and not treated with statin 
before hospitalization (on admission, 24 hours after primary 
PCI, at discharge)
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10.7) vs. 16.0 µg/dL (IQR 16.16) vs. 17.35 µg/dL (IQR 
15.3) respectively, p = 0.680).
Discussion
Statins are the first line drugs in primary and sec-
ondary prevention of atherosclerosis [7–8]. The high 
efficacy of these drugs results from widely document-
ed pleiotropic effects, including its anti-inflammatory 
activity [9–10]. The mechanism of action of statins and 
modulation of the inflammatory process is not fully un-
derstood [11], but a number of experimental and clinical 
studies confirm the beneficial effect of these drugs on 
inflammation process. One of the postulated routes 
of statins action is inhibition of activation NF-kappa B 
protein, which is one of the elements of the relay route 
for C-reactive protein [12]. 
A study by Hoffman has shown that statin pretreat-
ment in patients with AMI was associated with decreased 
systemic inflammation and better perfusion after primary 
angioplasty of the infarct-related artery [13]. In his study 
of 253 patients, divided into two groups: with statin pre-
treatment (n = 86) and control (n = 167), pretreatment 
was associated with a lower frequency of increased 
C-reactive protein (≥ 5 mg/L) on admission compared 
with the control group (48% vs. 64%; p = 0.019). In 
our study, the two groups differed significantly in CRP 
concentration only at discharge.
Very interesting findings were observed in the study 
evaluating the expression of CRP directly from the ma-
terial taken from the plaque during PCI (atherectomy 
in a vessel with stenosis > 80%) [14]. Previous therapy 
with statins in patients with ACS was associated with 
significantly lower expression of CRP within the lesion 
(p = 0.009). This effect was the same for all the types 
and doses of statins. However, there is a variation 
among the HMG-CoA inhibitors in their properties. The 
analysis of Prove IT-TIMI22 study indicated that there 
are differences in the effectiveness of different types 
of statins [15]. At the comparable levels of CRP at 
the beginning of the study (12.2 mg/L for atorvastatin 
and 11.9 mg/L for pravastatin, p = 0.60) there were 
significant differences in the level of C-reactive protein 
after 30 days (1.6 vs. 2.3 mg/L) and after 4 months 
(1.3 vs. 2.1 mg/L in favor of atorvastatin (p for all differ-
ences < 0.001.) A study conducted by Heart Protec-
tion Study Collaborative Group in patients with high 
cardiovascular risk, receiving a placebo or simvastatin 
(in a dose of 40 mg), has shown no significant relation-
ship between baseline CRP and reduction of the risk of 
cardiovascular events in the 5-year follow-up (vascular 
events: p = 0.41, coronary events p = 0.81) [16]. 
Thus, the future studies to discover which statins have 
Figure 4. Dynamics of changes in the concentrations 
of cortisol in two subgroups of patients: treated and not 
treated with statin before hospitalization (on admission, 
8 and 23 h after primary PCI)
the best potential to reduce the CRP and LDL-choles-
terol levels are needed.
Cytokines
Li et al., in their very interesting work, analyzed the 
changes in the concentrations of cytokines in patients 
with unstable angina and receiving 20 or 80 mg of sim-
vastatin [17]. It has been reported that in the group of 
20 mg/d, CRP decreased significantly from 5.6 mg/L at 
admission to 4.0 mg/L on the 14th day  of the study (28% 
reduction of the basic level of CRP). Furthermore, in the 
group that received 80 mg of simvastatin, the value of 
CRP of 5.7 mg/L at admission decreased significantly 
to 3.8 mg/L (33% reduction compared with the baseline 
level). The concentration of IL-10 in the group of 20 mg/d 
of simvastatin increased from 16.2 pg/mL at admission 
to 22.4 pg/mL on day 14 (p < 0.001) and, by analogy, 
from 15.8 pg/mL to 28.5 pg/mL in patients treated with 
the dose of 80 mg/d (p < 0.001). The existence of sig-
nificant inverse correlation between the concentrations 
of CRP and IL-10 on day 14 (at 20 mg/d, p < 0.05, for 
80 mg/d, p < 0.01) was also observed.
In our study the concentration and relative propor-
tions of CRP, pro-inflammatory IL- 6 and anti-inflam-
matory IL-10 were measured. CRP and IL-10 were 
identified as significant markers of inflammation. An 
increase in the proportion of pro- and anti-inflammatory 
cytokines was observed as well. The level of anti-in-
flammatory IL-10 on admission to the hospital was 
significantly lower in statin users before MI. We found 
no difference in concentration of pro-inflammatory 
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IL-6 among the subgroups. Decrease in the level of 
anti-inflammatory cytokines between 24 hours of hos-
pitalization and discharge from the hospital was higher 
in patients with history of statin intake, but due to the 
low number of patients did not reached the statistical 
significance. 
In the case of concentration of IL-6, the similar 
outcome was observed by Stefanadi et al., but in their 
study patients were treated with a different type of statin 
— atorvastatin. However, the study of Stefanadi et al. 
also confirmed the anti-inflammatory effect of low doses 
of atorvastatin [18]. The population of ST- elevation MI 
patients was treated with thrombolysis and atorvastatin 
(in dose 10 mg for 6 weeks). The measurements of 
the levels of cytokine were performed 6 hours after 
admission to hospital, after thrombolysis, after one 
week and after 6 weeks. There were no differences in 
the baseline concentrations of IL-6, and this effect was 
maintained even after one week. In both groups, there 
was a decrease of cytokine after 6 weeks, but only in 
the group receiving statin this outcome was statistically 
significant (p = 0.014). 
In the experimental model in rats, previously treated 
or untreated with atorvastatin for 4 weeks, myocardial 
infarction (LAD closure) was induced [19]. After a period 
of 4 weeks, subsequent echocardiography, ventricu-
lography and measurements of the levels of IL-6, TNFa 
and IL-10 (in the serum and in the myocardium) were 
performed. The results have shown that the adminis-
tration of statins has been associated with significantly 
lower levels of IL-6 and TNFa (for both p < 0.01). Fur-
thermore, the concentration of IL-10 was significantly 
higher (p < 0.01). TNFa/IL-10 ratio was significantly 
lower in the group receiving statins (p < 0.05).
Cortisol
Low serum cortisol concentrations have been asso-
ciated with adverse prognosis in critical illness of diverse 
etiology. Previous studies of the association between 
cortisol concentration and prognosis after acute myo-
cardial infarction are few and the results are conflicting. 
Zouaghi, in his study of just 34 patients, reported a neg-
ative association between cortisol concentration and 
the risk of death [1]. Only one study suggested that low 
cortisol concentration on admission is an adverse prog-
nostic indicator in patients with acute MI [2]. By contrast, 
three small studies of between 22 to 70 patients, with 
few deaths, suggested increased risk of death among 
patients with high cortisol concentrations [3–5]. In our 
study, cortisol concentration was significantly lower in 
the subgroup previously treated with statins at almost 
every measurement time point. It is possible that there 
are subgroups of patients in whom either very high or 
very low cortisol level confers an adverse prognosis in 
acute myocardial infarction, as in a more heterogeneous 
critical illness [6].
Weir et al. in their study found that higher levels of 
aldosterone and cortisol were associated with greater 
medium-term LV remodeling when measured in the 
first few days after AMI in patients with LVSD but no 
evidence of heart failure. Aldosterone and cortisol were 
also related to larger infarct volumes at baseline and 
greater infarct remodeling over time [20].
It may be suspected that there is a correlation 
between stress, cortisol release and production of 
cytokines. Nijm found that IL-6 is induced not only by 
inflammatory stimuli but also by acute stress, presum-
ably via catecholamines [21]. In his study, the coronary 
artery disease patients showed a cortisol pattern that 
markedly differed from healthy controls. It involved a flat-
ter diurnal slope and an attenuated cortisol response 
to acute stressors. Parallel to these findings, there was 
also a stress-induced increase in CRP that was specific 
to CAD patients. 
Studies of basal and stimulated hormones have 
been used to evaluate steroidogenesis in subjects on 
hepatic hydroxymethylglutaryl coenzyme A (HMG-CoA) 
reductase inhibitors. In our study, most of the patients 
were on simvastatin therapy. The researchers found 
that simvastatin in doses of up to 80 mg/d has no effect 
on adrenal and gonadal steroid production [22–24].
Limitations of the study
Several limitations of our study should be ac-
knowledged. First, the study has been designed in 
2004 based on then current guidelines and the available 
methods of lab tests. The recruitment was carried out 
in 2005–2008. All patients included into the study had 
bare metal stent implanted in accordance with ESC 
standards. This strategy provides a high homogeneity 
of the population and at the same time made it impos-
sible to compare the effect of the drug eluting stents, 
currently widely used, on the course of the inflammatory 
process. In order to precisely measure the onset of 
myocardial infarction we should reduce the time interval 
between the beginning of incidence and revascular-
ization. The assessment of the changes dynamics in 
the ST segment and its resolution would be a valuable 
analysis in this case. Patients receiving statins prior 
to AMI were not a homogenous group (4 patients on 
atorvastatin and 13 on simvastatin). Moreover, dosage 
and treatment period had not been available in source 
documentation so full analysis was not possible.
Currently, it is also recommended to perform the 
CRP assay with a high sensitivity method (hs-CRP). It 
should also be noted that performing a serial analysis 
of the inflammatory parameters between primary PCI 
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and 64 hours of hospitalization would be interesting 
for the study. The previously cited studies indicate that 
delayed peak of cytokines after approximately 48 hours 
is possible. Such change in the protocol of the study 
would allow to assess the dynamics of changes in the 
concentrations of cytokines — determine their maxi-
mum levels, the time to achieve the maximum level, and 
the time to return to the baseline. But the high costs of 
such procedure and nuisance for the patients made it 
impossible to perform.
To directly assess the impact of factors associated 
with PCI we also ought to take the blood samples from 
the aortic bulb, from the target coronary vessel right after 
the occlusion and from the coronary sinus, all in serial 
measurements. This project could help, by the index 
change between measuring points, to determine the 
place of synthesis and ejection of individual cytokines.
Conclusions
Statin therapy has a significant influence on cortisol 
level as well as on the profile of cardiac markers in 
patients with the first episode of ST-elevation myocar-
dial infarction undergoing pPCI with bare metal stent 
implantation. Patients previously treated with statins had 
significantly lower level of cortisol on admission and 
after 23 hours. No differences in pro- and anti-inflam-
matory cytokines concentration were observed. Future 
studies are needed to determine the clinical significance 
of these findings.
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